Investigating a new treatment for Alzheimer's disease and related dementia
Nonlipogenic ABCA1 inducers for ADRD
This study is looking at a new medication that could help people with Alzheimer's and related dementia by targeting certain proteins that affect cholesterol and inflammation, with the hope that it can improve brain function and overall health without causing weight gain.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10885017 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of medication that can help treat Alzheimer's disease and related dementia (ADRD) by targeting specific proteins involved in cholesterol metabolism and inflammation. The approach involves using a nonlipogenic ABCA1 inducer, which means it can increase the levels of a beneficial protein without causing unwanted fat accumulation in the liver. By optimizing drug discovery strategies, researchers aim to find compounds that can improve glucose metabolism and reduce inflammation, which are common issues in both ADRD and type 2 diabetes. Patients may benefit from this research if the new treatment proves effective in enhancing cognitive function and overall health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for Alzheimer's disease, particularly those with the APOE4 allele or those suffering from type 2 diabetes.
Not a fit: Patients with non-metabolic forms of dementia or those who do not carry the APOE4 allele may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that improves cognitive function and reduces the risk of Alzheimer's disease for patients.
How similar studies have performed: Other research has shown promise in targeting similar pathways for treating Alzheimer's disease, but this specific approach using nonlipogenic ABCA1 inducers is relatively novel.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Thatcher, Gregory R. J — University of Arizona
- Study coordinator: Thatcher, Gregory R. J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.